ClinicalTrials.gg
Enrolling by invitationNCT07064928WATUpdated Nov 2, 2026

Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women

An interventional study of Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 in HIV, HIV - Human Immunodeficiency Virus and Postpartum, sponsored by University of California, San Francisco. Enrolling by invitation at 1 site in Ghana. Open to female participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionDepressionRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2024, registered Jul 2025).
Updated Nov 2, 2026Enrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
14 Years and older
Sex
Female
01

Study summary

Purpose of this Study:

The main purpose of this study is to adapt an existing evidence-based intervention, Project Accept Post-Test Support Services (PTSS) Module 3, specifically for pregnant and postpartum women living with HIV (WLWH) in Ghana. The adapted intervention aims to reduce HIV-related stigma and improve adherence to antiretroviral therapy (ART) and mental health symptoms, such as depression and anxiety, among this vulnerable population.

Why was this study done? (Background):

HIV-related stigma is a major obstacle for women living with HIV, particularly pregnant women in Sub-Saharan Africa (SSA), hindering their engagement in HIV care and adherence to ART. This contributes to poor health outcomes, including inadequate viral suppression, depression, and an ongoing risk of HIV transmission to their children and sexual partners. While effective HIV stigma-reduction interventions exist for the general adult population living with HIV, there is a critical lack of tailored interventions for pregnant and postpartum WLWH in SSA. This study addresses this gap by adapting a proven intervention (Project Accept PTSS Module 3), which has shown success in reducing stigma and improving outcomes in other populations, for this specific group in Ghana, where HIV-related stigma remains disproportionately high.

Who participated in this study? (Target Population):

This study will involve several groups:

Pregnant and postpartum women living with HIV: 30 women will participate in in-depth interviews to share their experiences with stigma and HIV care.

HIV care providers: 20 providers will participate in in-depth interviews to offer their perspectives on stigma and care provision.

Stakeholders: This group will include HIV care providers, program administrators/directors, and pregnant and postpartum women. They will collaborate in the iterative process of adapting the intervention.

Pregnant women living with HIV (for feasibility testing): 90 pregnant women will be randomized, with half receiving the adapted intervention and half receiving standard care, to assess the intervention's feasibility, acceptability, and preliminary impact.

What happened in this study? (Intervention/Methods):

This 3-year study has three main aims:

Understanding Stigma Experiences: Researchers will describe the experiences of stigma and HIV care from the perspectives of pregnant and postpartum WLWH and compare them with providers' experiences. This will involve longitudinal data collection and in-depth interviews to understand how stigma affects women's health, clinical care (e.g., provider discrimination, ART adherence), and mental health over time.

Intervention Adaptation: Project Accept PTSS Module 3 will be adapted specifically for pregnant and postpartum WLWH using the ADAPT-ITT framework. This involves an iterative process with stakeholders to ensure the intervention is culturally and gender-appropriate, enhancing its acceptability for the target population.

Feasibility and Preliminary Impact Assessment: The study will assess the feasibility and acceptability of the adapted intervention. Ninety pregnant women will be randomly assigned to either receive the intervention or continue with standard care. Researchers will then estimate the intervention's potential impact on anticipated and internalized HIV-related stigma (primary outcomes), as well as ART adherence and symptoms of anxiety and depression (secondary outcomes).

What were the results of this study? (Outcomes):

As a preliminary and adaptation study, this research aims to:

Provide essential data to inform and justify a larger, fully-powered randomized clinical trial to rigorously evaluate the adapted intervention's effectiveness.

Identify potential indicators associated with mother-to-child transmission of HIV.

Develop a model that can be applied to other Sub-Saharan African countries facing similar challenges.

Foster new collaborations focused on HIV-related stigma among women in Ghana. Build research capacity among researchers in sub-Saharan Africa.

What are the side effects of the treatments in this study? (Safety):

This study focuses on a behavioral intervention (a support and counseling module) rather than a drug or medical treatment. Therefore, typical physical side effects associated with medications are not expected. The intervention aims to improve well-being and health outcomes by addressing psychosocial factors. Any adverse events or discomfort experienced by participants will be carefully monitored and addressed in accordance with ethical guidelines.

What are the conclusions of this study? (Implications/Future Plans):

The findings from this study are expected to demonstrate the feasibility and potential impact of a culturally and gender-tailored HIV stigma-reduction intervention for pregnant and postpartum WLWH in Ghana. This research will be foundational for launching a larger-scale clinical trial to definitively test the intervention's efficacy.

Read the detailed description

HIV-related stigma is a significant barrier to engagement in HIV care and adherence to antiretroviral therapy (ART), contributing to the ongoing global HIV epidemic. Stigma is a pervasive social experience in which people with marginalized attributes or identities are seen as having low social value and experience prejudice and discrimination. Globally, HIV-related stigma affects women more than men, and HIV-positive childbearing women experience even more intense stigma. In low-resource societies, pregnant women are often the first family members to receive HIV testing, a mandatory test during prenatal care, and are thus blamed and stigmatized for ostensibly bringing HIV into the family. HIV-related stigma in pregnant women also has adverse effects on infants and sero-discordant male sexual partners, who are at risk of HIV when stigma compromises the mother's ability to adhere to ART. HIV-related stigma is common in sub-Saharan Africa (SSA) where pregnant women have high HIV infection rates. HIV prevalence among women of childbearing age is increasing and this segment of the population is twice as likely to be HIV-positive than men of similar age. In SSA, HIV-related stigma among pregnant women results in poor care engagement, significant loss to follow-up, poor ART adherence, inadequate viral suppression, and depression. There is also ongoing risk of HIV transmission to their children and sexual partners. Thus, the need for intervention is critical to reducing the HIV-related stigma experienced by pregnant women in SSA to minimize loss to follow-up care and advance long-term efforts to successfully eliminate mother-to-child HIV transmission.

Prior evidence-based interventions for HIV stigma-reduction have focused on adults in the general population living with HIV but there is an absence of interventions to specifically reduce HIV stigma for pregnant and postpartum women living with HIV (WLWH) in SSA. One efficacious intervention designed for the general population is Project Accept, a US-designed multi-level intervention that significantly increased HIV testing and improved HIV outcomes. Project Accept's Post-Test Support Services (PTSS) Module 3 is specifically designed to reduce HIV-related stigma, encourage HIV treatment adherence, and improve quality of life among adults living with HIV. Participants in the United States (US) randomized to receive this module felt less stigmatized and had better ART adherence, higher retention in care, and improved well-being. The PTSS module was adapted for use in Tanzania, Nepal, South Africa and Thailand, where it led to a significant reduction in HIV-related stigma in the general population. Importantly, pregnant and postpartum WLWH were excluded from these studies.

To overcome this major gap, the investigators propose to adapt the Project Accept PTSS Module 3 specifically for pregnant and postpartum WLWH to reduce stigma and improve ART adherence and mental health symptoms of depression and anxiety. We selected Ghana in SSA for this research, where over 200,000 pregnant WLWH are placed on ART annually. While Ghana has one of the lowest HIV prevalence rates (2.3%) in SSA, the prevalence of HIV-related stigma is disproportionately high and a vast majority (≥85%) of adults express negative attitudes towards people living with HIV. The proposed intervention will be gender- and culturally-tailored to address HIV-related stigma and downstream effects on ART adherence and mental health. Our team is highly experienced in developing and testing behavioral interventions, and is conducting HIV-related stigma research in other countries within SSA. Our research aims to:

Aim 1: Describe experiences of stigma and HIV care for pregnant and postpartum WLWH compared with providers' experiences. Longitudinal data from pre- to post-natal periods and template analysis will be used to better understand women's perceptions of stigma over time and how it affects their health and clinical care (e.g., provider-based discrimination, experience of being pregnant and postpartum, mental health symptoms, adherence to ART, and HIV care engagement). The investigators will explore cultural and gender dimensions of stigma to inform the PTSS module adaptation and triangulate patient interview data (n=30) with data from providers (n=20) who will participate in in-depth interviews on their perspectives of HIV-related stigma, care provision in the context of stigma, and intervention needs.

Aim 2: Adapt Project Accept PTSS Module 3 to focus on HIV-related stigma, ART adherence, and mental health among pregnant and postpartum WLWH. Using the ADAPT-ITT framework, investigators will engage stakeholders including 1) HIV care providers, 2) program administrators/directors, and 3) pregnant and postpartum women in an iterative process of co-adapting PTSS to this population in order to establish cultural- and gender-saliency to increase the acceptability of the adapted intervention.

Aim 3: Assess feasibility and acceptability (F\&A) of the intervention and estimate the potential impact on HIV-related stigma among pregnant and postpartum WLWH. Investigators will randomize 90 pregnant women 1:1 to intervention or standard care controls to assess F\&A of the intervention and preliminary impact on outcomes. Our primary outcomes are anticipated and internalized HIV-related stigma. Secondary outcomes include ART adherence and mental health symptoms of anxiety and depression.

Overall Potential Impact: Results from this modular 3-year R01 will: 1) provide data needed to inform and justify a fully-powered randomized clinical trial to rigorously evaluate the adapted intervention for HIV-related stigma in pregnant and postpartum WLWH; 2) identify potential indicators associated with mother-to-child transmission of HIV; 3) serve as an applicable model for other SSA countries; 4) foster new collaborations focused on HIV-related stigma among women in Ghana; and 5) build capacity among researchers in SSA.

02

Conditions studied

  • HIV
  • HIV - Human Immunodeficiency Virus
  • Postpartum
  • Pregnancy
  • Mental Health (Depression)
  • Mental Health
  • Depression - Major Depressive Disorder
  • Stigma
  • Stigma, Social
  • Pyschological Distress

Keywords

  • stigma
  • hiv
  • self stigma
  • anticipated stigma
  • enacted stigma
  • stigma interventions
  • therapy
  • counseling
  • peer interventions
  • postpartum women
  • pregnant women
  • women living with HIV
03

In context

Depression Reclassified

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 163 is above the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with
  • Between 24-36 weeks gestation at enrollment
  • Willing to participate during the postpartum period

Recruitment process:

  • Approached during a prenatal visit by a nurse/midwife
  • Interested women will be connected with a trained research assistant (RA)
  • RA will explain the study to potential participants

Exclusion criteria

Exclusion criteria:

  • Critically ill and hospitalized pregnant WLWH
  • Pregnant WLWH not planning to live in the region for at least 6 months after childbirth
  • Pregnant WLWH under 13 years old, under parental supervision, and attending mandatory school

Eligibility of healthcare providers:

  • All providers at the four sites invited to a session at their site
  • Providers eligible if they have worked with WLWH or pregnant/postpartum women for at least 2 months
  • Providers who do not consent to be interviewed will not be included
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (estimated)

Study arms

  • Experimental
    Adapted Project Accept PTSS Module

    The adapted Project Accept's Post-Test Support Services (PTSS) Module 3 specifically designed to reduce HIV-related stigma, encourage HIV treatment adherence, and improve quality of life among those living with HIV.

    Behavioral: Adapted Project Accept's Post-Test Support Services (PTSS) Module 3

Interventions

  • BehavioralAdapted Project Accept's Post-Test Support Services (PTSS) Module 3

    Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 for the Ghanaian context, and among pregnant and/or postpartum women living with HIV

06

What researchers measure

Primary outcomes

  1. Mean change in anticipated HIV-related scale score

    Anticipated HIV-related stigma will be measured using Anticipated stigma scale. Response options range from 0-36 with higher scores indicating greater anticipated stigma.

    Time frame: Baseline and 6 weeks

  2. Mean change in internalized HIV-related scale score

    Internalized HIV-related stigma will be measured using 10 items Internalized Stigma Scale (ISAT). Response options range from 10-50 with higher scores indicating greater internalized stigma

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Mean change in Edinburgh Postnatal Depression Scale (EPDS) score

    Postnatal Depression will be measured using Edinburgh Postnatal Depression Scale (EPDS). Response options range from 0-30 with higher scores indicating greater internalized stigma

    Time frame: Baseline and 6 weeks

  2. Mean change in Center for Support Evaluation (CASE) scale score

    Self-report adherence will be estimated with the Center for Support Evaluation (CASE), Scores range from 3-16, and an index score of 10 or less indicates suboptimal adherence.

    Time frame: Baseline and 6 weeks

  3. Presence or Absence of tenofovir (TFV) in Urine

    Point-of-care rapid test to assess tenofovir (TFV) adherence in urine will used and an immunoassay cutoff of 1500 ng/mL will classify participants as adherent. Responses will be dichotomized to "adherent/ non-adherent"

    Time frame: Baseline and 6 weeks

07

Study locations

1 site
  • Ashaiman Polyclinic
    Accra, Ghana
08

References and documents

Publications

  • Nakimuli-Mpungu E, Okello J, Kinyanda E, Alderman S, Nakku J, Alderman JS, Pavia A, Adaku A, Allden K, Musisi S. The impact of group counseling on depression, post-traumatic stress and function outcomes: a prospective comparison study in the Peter C. Alderman trauma clinics in northern Uganda. J Affect Disord. 2013 Oct;151(1):78-84. doi: 10.1016/j.jad.2013.05.055. Epub 2013 Jun 17. PubMed 23787406 ↗
  • Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307. doi: 10.1007/s11904-014-0220-1. PubMed 25038748 ↗
  • Sakyi KS, Lartey MY, Kennedy CE, Denison JA, Sacks E, Owusu PG, Hurley EA, Mullany LC, Surkan PJ. Stigma toward small babies and their mothers in Ghana: A study of the experiences of postpartum women living with HIV. PLoS One. 2020 Oct 16;15(10):e0239310. doi: 10.1371/journal.pone.0239310. eCollection 2020. PubMed 33064737 ↗
  • Khumalo-Sakutukwa G, Morin SF, Fritz K, Charlebois ED, van Rooyen H, Chingono A, Modiba P, Mrumbi K, Visrutaratna S, Singh B, Sweat M, Celentano DD, Coates TJ; NIMH Project Accept Study Team. Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):422-31. doi: 10.1097/QAI.0b013e31818a6cb5. PubMed 18931624 ↗
  • Coates TJ, Kulich M, Celentano DD, Zelaya CE, Chariyalertsak S, Chingono A, Gray G, Mbwambo JK, Morin SF, Richter L, Sweat M, van Rooyen H, McGrath N, Fiamma A, Laeyendecker O, Piwowar-Manning E, Szekeres G, Donnell D, Eshleman SH; NIMH Project Accept (HPTN 043) study team. Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health. 2014 May;2(5):e267-77. doi: 10.1016/S2214-109X(14)70032-4. Epub 2014 Apr 8. PubMed 25103167 ↗
  • Turan JM, Nyblade L. HIV-related stigma as a barrier to achievement of global PMTCT and maternal health goals: a review of the evidence. AIDS Behav. 2013 Sep;17(7):2528-39. doi: 10.1007/s10461-013-0446-8. PubMed 23474643 ↗
  • Valencia-Garcia D, Rao D, Strick L, Simoni JM. Women's experiences with HIV-related stigma from health care providers in Lima, Peru: "I would rather die than go back for care". Health Care Women Int. 2017 Feb;38(2):144-158. doi: 10.1080/07399332.2016.1217863. Epub 2016 Aug 2. PubMed 27485767 ↗
  • Tran BX, Phan HT, Latkin CA, Nguyen HLT, Hoang CL, Ho CSH, Ho RCM. Understanding Global HIV Stigma and Discrimination: Are Contextual Factors Sufficiently Studied? (GAPRESEARCH). Int J Environ Res Public Health. 2019 May 29;16(11):1899. doi: 10.3390/ijerph16111899. PubMed 31146379 ↗
  • Turan B, Stringer KL, Onono M, Bukusi EA, Weiser SD, Cohen CR, Turan JM. Linkage to HIV care, postpartum depression, and HIV-related stigma in newly diagnosed pregnant women living with HIV in Kenya: a longitudinal observational study. BMC Pregnancy Childbirth. 2014 Dec 3;14:400. doi: 10.1186/s12884-014-0400-4. PubMed 25467187 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 15, 2025
StartActual
Nov 28, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
175→163
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Enrollment 175→163
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07064928
Collaborators
Fogarty International Center of the National Institute of Health, Africa Interdisciplinary Research Institute
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Nov 28, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Jerry J Ouner, PhD, RN, MS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion